Antibacterial and β-Lactamase Inhibitory Activity of Monocyclic β-Lactams

Medicinal Research Reviews

Volumn 38, Issue 2, 2018, Pages 426-503

  Decuyper, Lena ^a   Jukič, Marko ^b   Sosič, Izidor ^b   Žula, Aleš ^b   D'hooghe, Matthias ^a   Gobec, Stanislav ^b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

antibacterial drug design; monobactams; monocyclic lactams; siderophore; lactamase

Indexed keywords

3 [2 (2 AMINOTHIAZOL 4 YL) 2 (OXYIMINO) ACETAMIDO]MONOBACTAMS; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AROMATIC COMPOUND; AZETIDINE DERIVATIVE; BETA LACTAM DERIVATIVE; CHLOROCARDICINS; FORMADICINS; HYDROLASE INHIBITOR; MONOBACTAM DERIVATIVE; MONOCARBAMS; MONOPHOSPHAMS; MONOSULFACTAM; N1 SULFONYLOXY; NOCARDICIN A; PENICILLINASE; SIDEROPHORE; SUGAR; UNCLASSIFIED DRUG; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DERIVATIZATION; DRUG POTENCY; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; CHEMISTRY; METABOLISM;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; MONOBACTAMS; SIDEROPHORES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85033406293     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21443     Document Type: Review

References (219)

1. Fleming A. The antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B influenzae. Brit Exp Pathol 1929;10:226–236.
2. Tipper DJ. Mode of action of β-lactam antibiotics. Pharmacol Ther 1985;27:1–35.
3. Aoki H, Sakai H, Kohsaka M, Konomi T, Hosoda J, Kubochi Y, Iguchi E, Imanaka H. Nocardicin A, a new monocyclic β-lactam antibiotic. J Antibiot 1976;29:492–500.
4. Imada A, Kitano K, Kintaka K, Muroi M, Asai M. Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin. Nature 1981;289:590–591.
5. Sykes RB, Bonner DP. Aztreonam: The first monobactam. Am J Med 1985;78:2–10.
6. Page MI. The mechanisms of reactions of β-lactam antibiotics. Acc Chem Res 1984;17:144–151.
7. Turos E, Konaklieva MI, Ren RX-F, Shi H, Gonzalez J, Dickey S, Lim D. N-thiolated bicyclic and monocyclic β-lactams. Tetrahedron 2000;56:5571–5578.
8. Konaklieva M. Molecular targets of β-lactam-based antimicrobials: Beyond the usual suspects. Antibiotics 2014;3:128–142.
9. Cimarusti CM, Sykes RB. Monocyclic β-lactam antibiotics. Med Res Rev 1984;4:1–24.
10. Li L, Maoshuang, Zhao K, Tian A. Semi-empirical quantum chemical study on structure-activity relationship in monocyclic β-lactam antibiotics. J Mol Struc-Theochem 2001;545:1–5.
11. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010;23:160–201.
12. Konaklieva, MI. β-lactams as inhibitors of serine enzymes. Curr Med Chem: Anti-Infect Agents 2002;1:215–238.
13. Storace L, Anzalone L, Confalone PN, Davis WP, Fortunak JM, Giangiordano M, Haley Jr JJ, Kamholz K, Yin Li H, Ma P, Nugent WA, Parsons Jr RL, Sheeran PJ, Silverman CE, Waltermire RE, Wood CC. An efficient large-scale process for the human leukocyte elastase inhibitor, DMP 7771. Org Proc Res Dev 2002;6:54–63.
14. Firestone RA, Barker PL, Pisano JM. β-Lactam inhibitors of human leukocyte elastase. Tetrahedron 1990;46:2255–2262.
15. Slusarchyk WA, Bolton SA, Hartl KS, Huang M-H, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Sutton JC, Treuner U, Zahler R, Zhao G, Bisacchi GS. Synthesis of potent and highly selective inhibitors of human tryptase. Bioorg Med Chem Lett 2002;12:3235–3238.
16. Sutton JC, Bolton SA, Davis ME, Hartl KS, Jacobson B, Mathur A, Ogletree ML, Slusarchyk WA, Zahler R, Seiler SM, Bisacchi GS. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 2004;14:2233–2239.
17. Han WT, Trehan AK, Wright, JJK, Federici ME, Seiler SM, Meanwell NA. Azetidin-2-one derivatives as lnhibitors of thrombin. Bioorg Med Chem 1995;3:1123–1143.
18. Hanessian S, Sailes H, Therrien E. Synthesis of functionally diverse bicyclic sulfonamides as constrained proline analogues and application to the design of potential thrombin inhibitors. Tetrahedron 2003;59:7047–7056.
19. Aoyama Y, Uenaka M, Kii M, Tanaka M, Konoike T, Hayasaki-Kajiwara Y, Naya N, Nakajima M. Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors. Bioorg Med Chem 2001;9:3065–3075.
20. Delpiccolo CML, Mata EG. Efficient and selective solid-phase synthesis of trans-3-alkyl-β-lactams from nonactivated acid chlorides. Tetrahedron Lett 2004;45:4085–4088.
21. Burnett DA. β-Lactam cholesterol absorption inhibitors. Curr Med Chem 2004;11:1873–1887.
22. Guillon CD, Koppel GA, Brownstein MJ, Chaney MO, Ferris CF, Lu S, Fabio KM, Miller MJ, Heindel ND, Hunden DC, Cooper, RDG, Kaldor SW, Skelton JJ, Dressman BA, Clay MP, Steinberg MI, Bruns RF, Simon NG. Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem 2007;15:2054–2080.
23. Banik BK, Becker FF, Banik I. Synthesis of anticancer β-lactams: Mechanism of action. Bioorg Med Chem 2004;12:2523–2528.
24. Banik I, Becker FF, Banik BK. Stereoselective synthesis of β-lactams with polyaromatic imines: Entry to new and novel anticancer agents. J Med Chem 2003;46:12-15.
25. Beck TN, Lloyd D, Kuskovsky R, Minah J, Arora K, Plotkin BJ, Green JM, Boshoff HI, Barry C, Deschamps J, Konaklieva MI. Non-transpeptidase binding arylthioether β-lactams active against Mycobacterium tuberculosis and Moraxella catarrhalis. Bioorg Med Chem 2015;23:632–647.
26. Sperka T, Pitlik J, Bagossia P, Tozsera J. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorg Med Chem Lett 2005;15:3086–3090.
27. Goel RK. Evaluation of anti-hyperglycemic activity of some novel monocyclic beta-lactams. J Pharm Pharmaceut Sci 2004;7:80–83.
28. Kumar A, Rajput CS, Bhati SK. Synthesis of 3-4′-(p-chlorophenyl)-thiazol-2′-yl-2-(substituted azetidinone/thiazolidinone)-aminomethyl-6-bromoquinazolin-4-ones as anti-inflammatory agents. Bioorg Med Chem 2007;15:3089–3096.
29. Kumar A, Rajput CS. Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives. Eur Med Chem 2009;44:83–90.
30. Bhati SK, Kumar A. Synthesis of new substituted azetidinoyl and thiazolidinoyl-1,3,4-thiadiazino(6,5-b)indoles as promising anti-inflammatory agents. Eur Med Chem 2008;43:2323–2330.
31. Srivastava VK, Palit G, Singh S, Dhawan R, Shanker KJ. Thiouryl formazan, -thiazolidinone and -azetidinone derivatives as antiparkinsonian agents. Ind Chem Soc 1990;67:335–338.
32. Mehta PD, Sengar NPS, Pathak AK. Azetidin-2-one—A new profile of various pharmacological activities. Eur Med Chem 2010;45:5541–5560.
33. Galletti P, Giacomini D. Monocyclic β-lactams: New structures for new biological activities. Curr Med Chem Anti Infec Agents 2011;18:4265–4283.
34. Chu DTW, Plattner JJ, Katz L. New directions in antibacterial research. J Med Chem 1996;39:3853–3874.
35. King DT, Sobhanifar S, Strynadka NC. One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams. J Protein Sci 2016;25:787–803.
36. Sanders CC, Sanders WE. Beta-lactam resistance in Gram-negative bacteria: Global trends and clinical impact. Clin Infect Dis 1992;15:824–839.
37. Le Noc P. Monocyclic β-lactams. In: Bryskier AMD, Ed. Antimicrobial Agents: Antibacterials and Antifungals. Washington DC: ASM Press; 2005. p 336–347.
38. Phelan EK, Miraula M, Selleck C, Ollis DL, Schenk G, Mitić N. Metallo-β-lactamases: A major threat to human health. Am Mol Biol 2014;4:89–104.
39. Bebrone C, Lassaux P, Vercheval L, Sohier, J-S, Jehaes A, Sauvage E, Galleni M. Current challenges in antimicrobial chemotherapy focus on β-lactamase inhibition. Drugs 2010;70:651–679.
40. Williams, JD. β-Lactamases and β-lactamase inhibitors. Int Antimicrob Agents 1999;12(Suppl 1):S3–S7.
41. Essack SY. The development of β-lactam antibiotics in response to the evolution of β-lactamases. Pharm Res 2001;18:1391–1399.
42. Aranda MT, Pérez-Faginas P, González-Muñiz R. An update on the synthesis of β-lactams. Curr Org Synth 2009;6:325–341.
43. Singh GS, Sudheesh S. Advances in synthesis of monocyclic β-lactams. ARKIVOC 2014;1:337–385.
44. Sykes RB, Bonner DP, Swabb EA. Modern β-lactam antibiotics. Pharmacol Ther 1985;29:321–352.
45. Sykes RB, Cimarusti CM, Bonner DP, Bush K, Floyd DM, Georgopapadakou NH, Koster WA, Liu, WC, Parker WL, Principe PA, Rathnum ML, Slusarchyk WA, Trejo WH, Wells JS. Monocyclic β-lactam antibiotics produced by bacteria. Nature 1981;291:489–491.
46. Brewer NS, Hellinger WC. The monobactams. Mayo Clinic Proc 1991;66:1152–1157.
47. Parker WL, O'Sullivan J, Sykes RB. Naturally occurring monobactams. Adv Appl Microbiol 1986;31:181–205.
48. Czachor JS, Gleckman RA. Monobactams. In: Yoshikawa TT, Norman DC, Eds. Antimicrobial Therapy in the Elderly Patient. New York: Marcel Dekker; 1994. Vol 9, p 125–133.
49. Bonner DP, Sykes RB. Structure-activity relationships among the monobactams. J Antimicrob Chemother 1984;14:313–327.
50. Llarrull LI, Testero SA, Fisher JF, Mobashery S. The future of the β-lactams. Curr Opin Microbiol 2010;13:551–557.
51. Neu, HC. β-Lactam antibiotics: Structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis 1986;8(Suppl 3):S237–S259.
52. Slusarchyk WA, Dejneka T, Gordon EM, Weaver ER, Koster WA. Monobactams: Ring activating N-1-substituents in monocyclic β-lactam antibiotics. Heterocycles 1984;21:191–209.
53. Gootz TD. Discovery and development of new antimicrobial agents. Clin Microbiol Rev 1990;3:13–31.
54. Bonner DP, Whitney RR, Baughn CO, Miller BH, Olsen SJ, Sykes RB. In vivo properties of SQ 26, 776. J Antimicrob Chemother 1981;8(Suppl E):123–130.
55. Sykes RB, Bonner DP. Discovery and development of the monobactams. Rev Infect Dis 1985;7(Suppl 4):S579–S593.
56. Duma RJ. Aztreonam, the first monobactam. Ann Intern Med 1987;106:766–767.
57. Sykes RB, Koster WH, Bonner DP. The new monobactams: Chemistry and biology. J Clin Pharmacol 1988;28:113–119.
58. Hellinger WC, Brewer NS. Carbapenems and monobactams: Imipenem, meropenem, and aztreonam. Mayo Clinic Proc 1999;74:420–434.
59. Burgess DS, Summers KK, Hardin TC. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther 1999;21:1882–1889.
60. Masoud MS, Ali, AE, Nasr NM. Chemistry, classification, pharmacokinetics, clinical uses and analysis of β-lactam antibiotics: A review. J Chem Pharm Res 2014;6:28–58.
61. Fuchs PC, Jones PJ, Barry AL, Ayers LW, Gavan TL, Gerlach EH. in vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7620 consecutive clinical bacterial isolates. Diagn Microbiol Infect Dis 1986;54:345–349.
62. Roy C, Segura C, Reig R, Teixell M, Hermida M, Teruel D, Foz A. Activity of carumonam and aztreonam against Klebsiella species. Eur Clin Microbiol 1985;4:519–521.
63. Vurma-Rapp U, Kayser F-H. in vitro activity of carumonam (RO 17-2301) and twelve other antimicrobials against clinical isolates of Pseudomonas aeruginosa. Eur Clin Microbiol 1986;5:292–296.
64. Han S, Caspers N, Zaniewski RP, Lacey BM, Tomaras AP, Feng X, Geoghegan KF, Shanmugasundaram V. Distinctive attributes of β-lactam target proteins in Acinetobacter baumannii relevant to development of new antibiotics. J Am Chem Soc 2011;133:20536–20545.
65. Mendez R, Alemany T, Martin-Villacorta J. Catalysis of hydrolysis and aminolysis of non-clasical β-lactam antibiotics by metal ions and metal chelates. Chem Pharm Bull 1992;40:3228–3233.
66. 2+ catalysed hydrolysis of β-lactams: Experimental and theoretical studies on the influence of the β-lactam structure. New Chem 2004;28:15–25.
67. Papp-Wallace KM, Mallo S, Bethel CR, Taracila MA, Hujer AM, Fernandez A, Gatta JA, Smith KM, Xu Y, Page MGP, Desarbre E, Bou G, Bonomo RA. A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated Amp C cephalosporinase, by monocyclic β-lactams and carbapenems. J Antimicrob Chemother 2013;69:682–690.
68. Araoka H, Baba M, Takagi S, Matsuno N, Ishiwata K, Nakano N, Tsuji M, Yamamoto H, Seo S, Asano-Mori Y, Uchida N, Masuoka K, Wake A, Taniguchi S, Yoneyama A. Monobactam and aminoglycoside combination therapy against metallo-β-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a ‘break-point checkerboard plate’. Scand Infect Dis 2010;42:231–233.
69. Lister PD, Sanders WG, Sanders CC. Cefepime-aztreonam: A unique double β-lactam combination for Pseudomona saeruginosa. Antimicrob Agents Chemother 1998;42:1610–1619.
70. Panunzio M, Malabarba A, Vicennati P. Synthesis and antibacterial activity of new antibiotics arising from cephalosporin-monobactam coupling. ARKIVOC 2004;8:36–47.
71. Sendai M, Hashiguchi S, Tomimoto M, Kishimoto S, Matsuo T, Kondo M, Ochiai M. Chemical modification of sulfazecin: Synthesis of 4-(substituted methyl)-2-azetidinone-1-sulfonic acid derivatives. J Antibiotics 1985;38:346–371.
72. Weidekamm E, Stoeckel K, Egger, H.-J, Ziegler WH. Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic β-lactam, in humans. Antimicrob Agents Chemother 1984;26:898–902.
73. Kondo M, Kishimoto S, Ochiai M, Okonogi K, Imada A. in vitro and in vivo evaluation of AMA-1080 (Ro 17-2301), a new synthetic sulfazecin-type antibiotic. Proc Int Congr Chemother 13th 1983;4:56/51–56/55.
74. Imada A, Kondo M, Okonogi K, Yukishige K, Kuno M. in vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic β-lactam antibiotic. Antimicrob Agents Chemother 1985;27:821–827.
75. Bush K. Other β-lactams. In: O'Grady F, Finch RG, Lambert HP, Greenwood D, Eds. Antibiotic and Chemotherapy: Anti-Infective Agents and Their Use in Therapy. New York: Churchill Livingstone; 1997. p 306–327.
76. Wise R, Andrew JM, Piddock, LJV. The in vitro activity of RO 17-2301, a new monobactam, compared with other antimicrobial agents. J Antimicrob Chemother 1985;15:193–200.
77. Matsuda K, Hamana Y, Inoue M, Mitsuhashi S. in vitro antibacterial activity of AMA-1080. J Antimicrob Chemother 1985;16:539–547.
78. Breuer H, Cimarusti CM, Denzel T, Koster WH, Slusarchyk WA, Treuner UD. Monobactams: Structure-activity relationships leading to SQ 26,776. J Antimicrob Chemother 1981;8(Suppl E):21–28.
79. Neu H, Labthavikul P. in vitro activity and β-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents. Antimicrob Agents Chemother 1983;24:227–232.
80. Yoshioka K, Miyawaki T, Kishimoto S, Matsuo T, Ochiai M. Sulfazecin analogues preparation of 4-(fluoromethyl)-1-sulfo-2-azetidinone derivatives. J Org Chem 1984;49:1427–1430.
81. Kishimoto S, Sendai M, Tomimoto M, Hashiguchi S, Matsuo T, Ochiai M. Chemical modification of sulfazecin synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives. Chem Pharm Bull 1984;32:2646–2659.
82. Noguchi N, Masuya H, Sugawara T, Kawano Y, Matsuo T, Ochiai M. Synthesis and structure-activity relationships of azetidin-2-one-1-sulfonic acid derivatives with a heteroatom-bound substituent at the 4-position. J Antibiot 1985;38:1387–1400.
83. Matsuo T, Sugawara T, Masuya H, Kawano Y, Noguchi N, Ochiai M. Synthesis and antibacterial activity of 3-acylamino-2-azetidinone-1-sulfonic acid derivatives. Chem Pharm Bull 1983;31:1874–1884.
84. Skotnicki JS, Steinbaugh BA. Synthesis and antibacterial activity of novel aminothiazolyl β-lactam derivatives. J Antibiot 1986;39:372–379.
85. Matsuda K, Nakagawa S, Nakano F, Inoue M, Mitsuhashi S. Structure-activity relations of 4-fluoromethyl monobactams. J Antimicrob Chemother 1987;19:753–760.
86. Neu HC, Chin N-X. in vitro activity and β-lactamase stability of a new monobactam, B0-1165. Antimicrob Agents Chemother 1987;31:505–511.
87. Matsuda K, Sanada M, Nakagawa S, Inoue M, Mitsuhashi S. Preferential hydrolysis of cis-configuration compounds at the 3,4-position of monobactams by β-lactamase from Morganella morganii. Antimicrob Agents Chemother 1991;35:458–461.
88. Dugat D, Just G, Sahoo S. β-Lactams XII. A study of the synthesis of N-unsubstituted β-lactams, and of 4-styryl monobactams. Can Chem 1987;65:88–93.
89. Just G, Zamboni R. β-Lactams II. The synthesis of cis-N-(2′-carboxyphenyl)-3-phenylacetamido-4-methoxymethyl-2-azetidinone. Can Chem 1978;56:2720–2724.
90. Just G, Zamboni, R. β-Lactams. III The synthesis of 7-β-phenylacetamido-3′-carboxybenzo3,4-O-2-isocephem. Can Chem 1978;56:2725–2730.
91. Kim KS, Chambers JH. Synthesis and structure-activity relationships of C-4-amino acid substituted monobactam analogs. J Antibiot 1987;40:124–129.
92. Mewshaw RE, Commons TJ. Synthesis and antibacterial activity of C-4 substituted monobactams. J Antibiot 1987;40:1563–1571.
93. Yamashita H, Minami N, Sakakibara K, Kobayashi S, Ohno M. Synthesis of 4-(methoxyethyl) monobactams by a chemoenzymatic approach. Chem Pharm Bull 1988;36:469–480.
94. Yamashita H, Minami N, Sakakibara K. Monocyclic β-lactam antibiotics: Synthesis and antibacterial activity of 4-(substituted ethyl)-2-azetidinone-1-sulfonic acid derivatives. J Antibiot 1987;40:1716–1732.
95. Branch CL, Finch SC, Pearson MJ. Synthesis of novel 3-formamido-3-acylamino-monobactams. Tetrahedron Lett 1989;30:3219–3222.
96. Arnould JC, Boutron P, Pasquet MJ. Synthesis and antibacterial activity of C4 substituted monobactams. Eur Med Chem 1992;27:131–140.
97. Guanti G, Riva R, Cascio G, Manghisi E, Morandotti G, Satta G, Sperning R. A new class of cis-monobactam derivatives bearing a sulfamoyloxymethyl or an N-alkylsulfamoyloxymethyl group at position 4: Synthesis and antibacterial activity. Farmaco 1998;53:173–180.
98. Wheeler W, Finley DR, Ott JL. The synthesis and biological evaluation of some novel aminoheterocyclic methoxime monobactam derivatives. J Antibiot 1986;39:1611–1614.
99. Okonogi K, Sugiura A, Kuno M, Ono H, Harada S, Higashide E. Interactions of formylamino- and methoxy-substituted β-lactam antibiotics with β-lactamases. J Antibiot 1985;38:1555–1563.
100. Kato T, Hinoo H, Terui Y, Nishikawa J, Nakagawa Y, Ikenishi Y, Shoji J. PB-2566 A, B and C, new monobactams I. Taxonomy, fermentation and isolation. J Antibiot 1987;40:135–138.
101. Kato T, Hinoo H, Terui Y, Nishikawa J, Nakagawa Y, Ikenishi Y, Shoji J. PB-2566 A, B and C, new monobactams II. Physico-chemical properties and chemical structures. J Antibiot 1987;40:139–144.
102. Box SJ, Brown AG, Gilpin ML, Gwynn MN, Spear, SR MM 42842, a new member of the monobactam family produced by Pseudomonas cocovenenans II. Production, isolation and properties of MM 42842. J Antibiot 1988;41:7–12.
103. Obi K, Ito Y, Terashima S. Synthesis of novel monobactams bearing an (R)-1-hydroxyethyl group and an (S)-1-carbamoyloxyethyl group at the C3,4-positions. Chem Pharm Bull 1990;38:917–924.
104. Nagy J, Nyitrai J, Kajtar-Peredy M. Simple and Condensed β-lactams, XVII. Monobactams acylated with isoxazoleacetic and isoxazolecarboxylic acids. Liebigs Ann Chem 1993;1993:815–821.
105. Bulychev A, Massova I, Lerner SA, Mobashery S. Penem BRL 42715: An effective invactivator for β-lactamases. J Am Chem Soc 1995;117:4797–4801.
106. Philips OA, Czajkowski DP, Atchinson K, Micetich RG, Maiti SN, Kunugita C, Hyodo A. Studies on monobactams I Synthesis and β-lactamase inhibitory activity of 4-substituted 3-(N-methyl-1,2,3-triazol-4-yl)-methylene-2-azetidinone-1-sulfonates. Chem Heterocycl Compd 1998;34:1308–1318.
107. Adediran SA, Lohier JF, Cabaret D, Wakselman M, Pratt RF. Synthesis and reactivity with β-lactamases of a monobactam bearing a retro-amide side chain. Bioorg Med Chem Lett 2006;16:869–871.
108. Livermore DM, Chen HY, Potentiation of β-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of Amp C β-lactamases. J Antimicrob Chemother 1997;40:335–343.
109. Pörnull KJ, Rodrigo G, Dornbusch K. Production of a plasmid-mediated Amp C-like β-lactamase by a Klebsiella pneumoniae Septicaemia isolate. J Antimicrob Chemother 1994;34:943–954.
110. Heinze-Krauss I, Angerhrn P, Charnas RL, Gubernator K, Gutknecht, E.-M, Hubschwerlen C, Kania M, Oefner C, Page MG, Sogabe S, Specklin J-L, Winkler F. Structure-based design of β-lactamase inhibitors 1. Synthesis and evaluation of bridged monobactams. J Med Chem 1998;41:3961–3971.
111. Blizzard TA, Chen H, Kim S, Wu J, Young K, Park Y-W, Ogawa A, Raghoobar S, Painter RE, Hairston N, Lee SH, Misura A, Felcetto T, Fitzgerald P, Sharma N, Lu J, Ha S, Hickey E, Hermes J, Hammond ML. Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1 Discovery of a class C BLI for combination with imipinem. Bioorg Med Chem Lett 2010;20:918–921.
112. Chen H, Blizzard TA, Kim S, Wu J, Young K, Park Y-W, Ogawa AM, Raghoobar S, Painter RE, Wisniewski D, Hairston N, Fitzgerald P, Sharma N, Scapin G, Lu J, Hermes J, Hammond ML. Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2 N-Alkylated and open chain analogues of MK-8712. Bioorg Med Chem Lett 2011;21:4267–4270.
113. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 2010;65:2382–2395.
114. Page MGP, Dantier C, Desarbre E, Gaucher B, Gebhardt K, Schmitt-Hoffmann A. in vitro and In vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple β-lactamases. Antimicrob Agents Chemother 2011;55:1510–1519.
115. Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MGP, Drawz SM, Bonomo RA. Enhancing resistance to cephalosporins in class C β-lactamases: Impact of Gly 214 Glu in CMY-2. Biochemistry 2010;49:1014–1023.
116. Gordon EM, Ondetti MA, Pluscec J, Cimarusti CM, Bonner DP, Sykes RB. O-sulfated β-lactam hydroxamic acids (monosulfactams). Novel monocyclic β-lactam antibiotics of synthetic origin. J Am Chem Soc 1982;104:6053–6060.
117. Yoshida C, Hori T, Momonoi K, Nagumo K, Nakano J, Kitani T, Fukuoka Y, Saikawa I. Studies on monocyclic beta-lactam antibiotics. II. Synthesis and antibacterial activity of 3-acylamino-2-azetidinone-1-oxysulfonic acids. J Antibiot 1985;38:1536–1549.
118. Hubschwerlen C, Angehrn P, Gubernator K, Page MGP, Specklin JL. Structure-based design of β-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins. J Med Chem 1998;41:3972–2975.
119. Tanaka SK, Summerill RAS, Minassian BF, Bush K, Visnic DA, Bonner DP, Sykes RB. in vitro evaluation of tigemonam, a novel oral monobactam. Antimicrob Agents Chemother 1987;31:219–225.
120. Chin N-X, Neu HC. Tigemonam, an oral monobactam. Antimicrob Agents Chemother 1988;32:84–91.
121. Brown J, Yang Y, Livermore DM. in vitro activity of tigemonam, an oral monobactam, against Gram-negative rods, including variants in β-lactamase-production. J Antimicrob Chemother 1989;23:201–207.
122. Sykes RB, Koster WH, Bonner DP. The new monobactams: Chemistry and biology. J Clin Pharmacol 1988;28:113–119.
123. Bush K, Smith SA, Tanaka SK, Bonner DP. Inactivation of β-lactamases from Enterobacter cloacae by monophosphams. J Antimicrob Chemother 1988;22:801–809.
124. Dobrowolski JCz, Sadlej J, Mazurek AP. The model monobactam and nocardicin—An ab initio calculation. J Mol Struct 2003;638:229–234.
125. Angehrn P, Hall MJ, Lloyd WJ, Westmacott D. Synergistic antibacterial activity between L-norvalyl L-1-aminoethylphosphonic acid and nocardicin A. Antimicrob Agents Chemother 1984;25:607–611.
126. Kelley WL, Townsend CA. Mutational analysis of noc K and noc L in the nocardicin A producer Nocardia uniformis. J Bacteriol 2005;128:739–746.
127. Isenring HP, Hofheinz W. A total synthesis of nocardicins. Tetrahedron 1983;39:2591–2597.
128. Kelley WL, Townsend CA. Mutational analysis and characterization of nocardicin C-9′ epimerase. J Biol Chem 2004;279:38220–38227.
129. Gunsior M, Breazeale SD, Lind AJ, Ravel J, Janc JW, Townsend CA. The biosynthetic gene cluster for a monocyclic β-lactam antibiotic, nocardicin A. Chem Biol 2004;11:927–938.
130. Kojo H, Mine Y, Nishida M, Goto S, Kuwahara S. Nature of monocyclic β-lactam antibiotic nocardicin A to β-lactamases. Microbiol Immunol 1988;32:119–130.
131. Hosoda J, Konomi T, Tani N, Aoki H, Imanaka H. Biosynthesis of nocardicin A by Nocardia uniformis subsp tsuyamanensis. 2. Isolation of new nocardicins from Nocardia uniformis subsp. tsuyamanensis. Agric Biol Chem 1977;41:2013–2020.
132. Townsend CA, Salituro GM. Total syntheses of (-)-nocardieins A-G: A biogenetic approach. J Am Chem Soc 1990;112:760–770.
133. Nakaguchi O, Oku T, Takeno H, Hashimoto M, Kamiya T. Enantioselective synthesis of monocyclic β-lactams related to nocardicins via a 2 + 2 cycloaddition reaction. Chem Pharm Bull 1987;35:3985–3994.
134. Nakaguchi O, Oku T, Takeno H, Hashimoto M, Kamiya T. Preparation of 3-aminonocardicinic acid and its acyl derivatives. Chem Pharm Bull 1987;35:3979–3984.
135. Gerardin-Charbonnier C, Auberger S, Molina L, Achilefu S, Manresa MA, Vinardell P, Infante MR, Selve C. Preparation and antibiotic activity of monobactam analogues of nocardicins. Prep Biochem Biotechnol 1999;29:257–272.
136. Hwu JR, Ethiraj KS, Hakimelahi GH. Biological activity of some monocyclic- and bicyclic β-lactams with specified functional groups. Mini Rev Med Chem 2003 3, 305–313.
137. Hakimelahi GH, Tsay S-C, Hwu JR. Synthesis of a masked p-quinone methide β-lactam as an active metabolite of nocardicins. Helv Chim Acta 1995;78:411–420.
138. Hakimelahi GH, Just, G. β-Lactams VI. The synthesis of homocycloanalogues of nocardicin A. Can Chem 1979;57:1939–1944.
139. Heck JV, Christensen BG. Nuclear analogues of β-lactam antibiotics I. The synthesis of 6β-amidocyclonocardicins. Tetrahedron Lett 1981;22:5027–5030.
140. Nisbet LJ, Mehta RJ, Oh Y, Pan CH, Phelen CG, Polansky MJ, Shearer MC, Giovenella AJ, Grappel SF. Chlorocardicin, a monocyclic β-lactam from a Streptomyces sp I. Discovery, production and biological activities. J Antibiot 1985;38:133–138.
141. Chan JA, Shultis EA, Dingerdissen JJ, De Brosse CW, Roberts GD, Snader KM. Chlorocardicin, a monocyclic β-lactam from a Streptomyces sp II. Isolation, physico-chemical properties and structure determination. J Antibiot 1985;38:139–144.
142. Katayama N, Nozaki Y, Okonugi K, Ono H, Harada S, Okazaki H. Formadicins, new monocyclic β-lactam antibioticsof bacterial origin I. Taxonomy, fermentation and biological activities. J Antibiot 1985;38:1117–1127.
143. Hida T, Tsubotani S, Katayama N, Okazaki H, Harada S. Formadicins, new monocyclic β-lactam antibioticsof bacterial origin II. Isolation, characterization and structures. J Antibiot 1985;38:1128–1140.
144. Breuer H, Straub H, Treuner UD, Drossard J-M, Höhn H, Lindner KR. (2-Oxo-1-azetidinyl)oxyacetic acids: A new class of synthetic monobactams. J Antibiot 1985;38:813–818.
145. Woulfe SR, Miller M. J Synthesis and biological activity of substituted 3(S)-(acylamino)-2-oxo-1-azetidinyloxyacetic acids. A new class of heteroatom-activated β-lactam antibiotics. J Med Chem 1985;28:1447–1453.
146. García-Rodriguez JA, García-Sánchez JE, Plata A, Trujillano I. The in vitro activity of SQ 82,291, a new monobactam, in comparison with aztreonam. J Antimicrob Chemother 1986;17:303–307.
147. Woulfe SR, Miller MJ. The synthesis of substituted 3(S)-(acylamino)-2-oxo-1-azetidinylthioacetic acids. J Org Chem 1986;51:3133–3139.
148. Boyd DB, Eigenbrot C, Indelicato JM, Miller MJ, Pasini CE, Woulfe SR. Heteroatom-activated β-lactam antibiotics: Considerations of differences in the biological activity of 3(S)-(acylamino)-2-oxo-1-azetidinyloxyacetic acids (oxamazins) and the corresponding sulful analogues (thiamazins). J Med Chem 1987;30:528–536.
149. Bulychev A, O'Brien ME, Massova I, Teng M, Gibson TA, Miller MJ, Mobashery S. Potent mechanism-based inhibition of the TEM-1 β-lactamase by novel N-sulfonyloxy β-lactams. J Am Chem Soc 1995;117:5983–5943.
150. Swarén P, Massova I, Bellettini JR, Bulychev A, Maveyraud L, Kotra LP, Miller MJ, Mobashery S, Samama J-M. Elucidation of mechanism of inhibition and X-ray structure of the TEM-1 β-lactamase from Escherichia coli inhibited by a N-sulfonyloxy-β-lactam. J Am Chem Soc 1999;121:5353–5359.
151. Mourey L, Kotra LP, Bellettini J, Bulychev A, O'Brien M, Miller MJ, Mobashery S, Samama JM. Inhibition of the broad spectrum nonmetallocarbapenamase of class A (NMC-A) β-lactamase from Enterobacter cloacae by monocyclic β-lactams. J Biol Chem 1999;274:25260–25265.
152. Bulychev A, Bellettini JR, O'Brien M, Crocker PJ, Samama J-M, Miller MJ, Mobashery S. N-sulfonyloxy-β-lactam inhibitors for β-lactamases. Tetrahedron 2000;56:5719–5728.
153. Bhattacharya B, Turos E. Synthesis and biology of N-thiolated β-lactams. Tetrahedron 2012;68:10665–10685.
154. Revell KD, Heldreth B, Long TE, Jang LS, Turos E. N-Thiolated β-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus. Bioorg Med Chem Lett 2007;15:2453–2467.
155. Coates C, Long TE, Turos E, Dickey S, Lim DV. N-Thiolated β-lactam antibacterials: Defining the role of unsaturation in the C4 side chain. Bioorg Med Chem Lett 2003;11:193–196
156. Turos E, Coates C, Shim J-J, Wang Y, Leslie M, Long TE, Reddy, GSK, Ortiz A, Culbreath M, Dickey S, Lim DV, Alonso E, Gonzales J. N-Methylthio β-lactam antibacterials: Effects of the C3/C4 ring substituents on anti-MRSA activity. Bioorg Med Chem Lett 2005;13:6289–6308.
157. Long TE, Turos E, Konaklieva MI, Blum AL, Amry A, Baker EA, Suwandi LS, Mc Cain MD, Rahman MF, Dickey S, Lim DV. Effect of aryl ring fluorination on the antibacterial properties of C4 aryl-substituted N-methylthio β-lactams. Bioorg Med Chem 2003;11:1859–1863.
158. Turos E, Long TE, Konaklieva MI, Coates C, Shim J-Y, Dickey S, Lim DV, Cannons A. N-Thiolated β-Lactams: Novel antibacterial agents for methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett 2002;12:2229–2231.
159. Turos E, Long TE, Heldreth B, Leslie JM, Reddy GSK, Wang Y, Coates C, Konaklieva M, Dickey S, Lim DV, Alonso E, Gonzales J. N-Thiolated β-lactams: A new family of anti-Bacillus agents. Bioorg Med Chem Lett 2006;16:2084–2090.
160. Jarrahpour A, Motamedifar M, Zarei M, Youssoufi MH, Mimouni M, Chohan ZH, Hadda TB. Petra, osiris, and molinspiration together as a guide in drug design: Predictions and correlation structure/antibacterial activity relationships of new N-sulfonyl monocyclic β-lactams. Phosphorus Sulfur Silicon 2010;185:491–497.
161. Jarrahpour A, Motamedifar M, Zarei M, Mimouni M. Synthesis of new N-sulfonyl monocyclic β-lactams and the investigation of their antibacterial activities. Phosphorus Sulfur Silicon 2010;185:287–297.
162. Galletti P, Cocuzza, CEA, Pori M, Quintavalla A, Musumeci R, Giacomini D. Antibacterial agents and cystic fibrosis: Synthesis and antimicrobial evaluation of a series of N-thiomethylazetidinones. Chem Med Chem 2011;6:1919–1927.
163. Carvellati R, Galletti P, Greco E, Cocuzza, CEA, Musumeci R, Bardini L, Paolucci F, Pori M, Soldati R, Giacomini D. Monocyclic β-lactams as antibacterial agents: Facing antioxidant activity of N-methylthio-azetidinones. Eur Med Chem 2013;60:340–349.
164. Majewski MW, Watson KD, Cho S, Miller PA, Franzblau SG, Miller MJ. Syntheses and biological evaluations of highly functionalized hydroxamate containing and N-methylthio monobactams as anti-tuberculosis and β-lactamase inhibitory agents. Med Chem Comm 2016;7:141–147.
165. Pawar RB, Mulwad VV. Synthesis of some biologically active pyrazole, thiazolidinone and azetidinone derivatives. Chem Heterocycl Compd 2004;40:219–226.
166. Halve AK, Bhadauria D, Dubey R. N/C-4 substituted azetidin-2-ones: Synthesis and preliminary evaluation as new class of antimicrobial agents. Bioorg Med Chem Lett 2007;17:341–345.
167. Bhat KI, Chaithanya SK, Satyanarayana PD, Kalluraya B. The synthesis and antimicrobial study of some azetidinone derivatives with the para-anisidine moiety. J Serb Chem Soc 2007;7:437–442.
168. Samadhiya P, Sharma R, Srivastava SK, Srivastava SD. Synthesis of 2-oxoazetidine derivatives of 2-aminothiazole and their biological activity. J Serb Chem Soc 2012;77:599–605.
169. Chavan AA, Pai NR. Synthesis and biological activity of N-substituted-3-chloro-2-azetidinones. Molecules 2007;12:2467–2477.
170. Rajput N, Sikarwar AK. Synthesis, spectral analysis and invitro biological evaluation of azetidinone derivatives of 5-nitroindazole. Heterocycl Lett 2013;3:191–196.
171. Walmik P, Saundane AR. Synthesis of novel indolyl-azetidinone and thiazolidinone derivatives as a potent antioxidant, antimicrobial and antitubercular agents. Der Pharma Chem 2014;6:70–79.
172. Singh I, Kumar A. Synthesis, characterization and antimicrobial activity of some newly 1,2,4-triazole derivatives. IJSPR 2014;5:4386–4394.
173. Nadia, AAE, Nesrin, MMM. Synthesis and antimicrobial activity of β-lactams: Antibacterial activities and antifungal activities. Heterocycl Lett 2014;4:153–182.
174. Pagadala R, Meshram JS, Chopde HN, Jetti V, Chidurala P, Kusampally U. Synthesis and antimicrobial evaluation of new monocyclic β-lactams. J Heterocyclic Chem 2012;49:1151–1155.
175. Curran WV, Lenhard RH. N-Azamonobactams 2. Synthesis of some N-iminoacetic acid and N-glycosil analogues. J Med Chem 1989;32:1749–1753.
176. Jarrahpour AA, Shekarriz MM, Taslimi A. Synthesis and antimicrobial activity of some new sugar based monocyclic β-lactams. Molecules 2004;9:29–38.
177. Hassan HHAM, Soliman R. Synthesis and antimicrobial activity of novel 3-benzyloxy-4-substituted azetidin-2-ones: Formation of a hydrophobic layer via a self-organization effect. Phosphorus Sulfur Silicon 2011;186:1932–1947.
178. Broccolo F, Cainelli G, Caltabiano G, Cocuzza CEA, Fortuna CG, Galletti P, Giacomini D, Musumarra G, Musumeci R, Quintavalla A. Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: New products with promising antibiotic activity against resistant bacteria. J Med Chem 2006;49:2804–2811.
179. Turner JG. Tabtoxin, produced by Pseudomonas tabaci, decreases Nicotiana tabacum glutamine synthetase in vivo and causes accumulation of ammonia. Physiol Plant Pathol 1981;19:57–67.
180. Thomas MD, Langston-Unkefer PJ, Uchytil TF, Durbin RD. Inhibition of glutamine synthetase from pea by tabtoxinine-β-lactam. Plant Physiol 1983;71:912–915.
181. Yoshida C, Tanaka K, Nakano J, Todo Y, Yamafuji T, Hattori R, Fukuoka Y, Saikawa I. Studies on monocyclic β-lactam antibiotics III. Synthesis and antibacterial activity of N-(aromatic heterocyclic substituted) azetidin-2-ones. J Antibiotics 1986;391:76–89.
182. Yoshida C, Tanaka K, Todo Y, Hattori R, Fukuoka Y, Komatsu M, Saikawa I. Studies on monocyclic β-lactam antibiotics IV. Synthesis and antibacterial activity of (3,4)-3-2-(2-aminothiazol-4-yl)-(Z)-2-(O-substituted oxyimino) acetamido-4-methyl-1-(1-tetrazol-5-yl)-2-azetidinones. J antibiotics 1986;39:90–100.
183. Yoshida C, Tanaka K, Hattori R, Fukuoka Y, Komatsu M, Kishimoto S, Saikawa I. Studies on monocyclic β-lactam antibiotics V. Synthesis and antibacterial activity of 3-2-(2-aminothiazol-4-yl)-(Z)-2-(O-substituted oxyimino) acetamido-1-(1-tetrazol-5-yl)-2-azetidinones having various functional groups at C-4 position of β-lactam. J antibiotics 1986;39:215–229.
184. Chantot JF, Klich M, Teutsch G, Bryskier A, Collette P, Markus A, Seibert G. Antibacterial activity of RU44790, a new N-tetrazolyl monocyclic β-lactam. Antimicrob Agents Chemother 1992;36:1756–1763.
185. Cerić H, Šindler-Kulyk M, Kovač ević M, Perić M, Živkovič A. Azetidinone-isothiazolidinones: Stereoselective synthesis and antibacterial evaluation of new monocyclic beta-lactams. Bioorg Med Chem 2010;18:3053–3058.
186. Keri RS, Hosamani KM, Reddy HS, Shingalapur RV. Synthesis, in vitro antimicrobial and cytotoxic studies of novel azetidinone derivatives. Arh Pharm Chem Life Sci 2010;343:237–247.
187. Singh GS, Mbukwa E, Pheko T. Synthesis and antimicrobial activity of new azetidin-2-ones from N-(salicylidene) amines and 2-diazo-1,2-diarylethanones. ARKIVOC 2007;9:80–90.
188. Shah RS, Modi NR, Patel MJ, Patel LJ, Chauhan BF, Patel MM. Design, synthesis and in vitro antibacterial and antifungal activities of some novel spiroazetidine-2,3′-indole-2,4(1′H)-dione. Med Chem Res 2011;20:587–594.
189. Harrington J M, Gootz T, Flanagan M, Lall M, O'Donnell J, Winton J, Mueller J, Crumbliss AL. Characterization of the aqueous iron(III) chelation chemistry of a potential Trojan Horse antimicrobial agent: Chelate structure, stability and pH dependent speciation. Biometals 2012;25:1023–1036.
190. Page MGP. Siderophore conjugates. Ann NY Acad Sci 2013, 1277, 115–126.
191. Möllman U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D. Siderophores as drug delivery agents application of the Trojan Horse strategy. Biometals 2009;22:615–624.
192. Bush K. Improving known classes of antibiotics: An optimistic approach for the future. Curr Opin Pharmacol 2012;12:527–534.
193. Barbachyn MR, Tuominen TC. Synthesis and structure-activity relationships of monocarbams leading to U-78608. J Antibiot 1990;43:1199–1203.
194. Zurenko GE, Truesdell SE, Yagi BH, Mourey RJ, Laborde AL. in vitro antibacterial activity and interactions with β-lactamases and Penicillin-binding proteins of the new monocarbam antibiotic U-78608. Antimicrob Agents Chemother 1998;34:884–888.
195. Nikaido H, Rosenberg EY. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: Study with β-lactam antibiotics containing catechol and analogous groups. J Bacteriol 1990;172:1361–1367.
196. Cheng J, Juarez-Hernandez RE, Miller MJ. Exploring bacterial iron acquisition: Siderophore conjugates. Future Med Chem 2012;4:297–313.
197. Han S, Zaniewski RP, Marr ES, Lacey BM, Tomaras AP, Evdokimov A, Miller JR, Shanmugasundaram V. Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2010;107:22002–22007.
198. Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Benzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD. Preparation, Gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. ACS Med Chem Lett 2011;2:285–390.
199. Mc Pherson CJ, Aschenbrenner LM, Lacey BM, Fanhoe KC, Lemmon MM, Finegan SM, Tadakamalla B, O'Donnell JP, Mueller JP, Tomaras AP. Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam. Antimicrob Agents Chemother 2012;56:6334–6342.
200. Murphy-Benenato KE, Bhagunde PR, Chen A, Davis HE, Durand-Réville TF, Ehmann DE, Galullo V, Harris JJ, Hatoum-Mokdad H, Jahić H, Kim A, Manjunatha MR, Manyak EL, Mueller J, Patey S, Quiroga O, Rooney M, Sha L, Shapiro AB, Sylvester M, Tan B, Tsai AS, Uria-Nickelsen M, Wu Y, Zambrowski M, Zhao SX. Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamics model. J Med Chem 2015;58:2195–2205.
201. Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D. Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother 1997;41:1010–1016.
202. Nishida K, Kunugita C, Uji T, Higashitani F, Hyodo A, Unemi N, Maiti SN, Phillips OA, Spevak P, Atchison KP, Salama SM, Atwal H, Micetich RG. in vitro and in vivo of Syn 2190, a novel β-lactamase inhibitor. Antimicrob Agents Chemother 1999;43:1895–1900.
203. Netzel TC, Jindani I, Hanson N, Turner BM, Smith L, Rand KH. The Amp C inhibitor, Syn 2190, can be used to reveal extended-spectrum β-lactamases in Escherichia coli. Diagn Microbiol Infect Dis 2007;58:345–348.
204. Mitton-Fry MJ, Arcari JT, Brown MF, Casavant JM, Finegan SM, Flanagan ME, Gao H, George DM, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Irvine R, Lall MS, Megan Lemmon M, Li C, Lin J, McCurdy SP, Mueller JP, Mullins L, Niosi M, Noe MC, Pattavina D, Penzien J, Plummer MS, Risley H, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Winton J, Young JA. Novel monobactams utilizing siderophore uptake mechanisms for the treatment of Gram-negative infections. Bioorg Med Chem Lett 2012;22:5989–5994.
205. Brown MF, Mitton-Fry MJ, Arcari JT, Barham R, Casavant J, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Lall MS, Lemmon MM, Li C, Lin J, McCurdy SP, McElroy E, McPherson C, Marr ES, Mueller JP, Mullins L, Nikitenko AA, Noe MC, Penzien J, Plummer MS, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Tomaras A, Young JA, Zaniewski RP. Pyridone-conjugated monobactam antibiotics with Gram-negative activity. J Med Chem 2013;56:5541–5552.
206. Hai-Gen F, Xin-Xin H, Cong-Ran L, Ying-Hong L, Yan-Xiang W, Jian-Dong J, Chong-Wen B, Sheng T, Xue-Fu Y, Dan-Quing S. Design, synthesis and biological evaluation of monobactams as antibacterial agents against Gram-negative bacteria. Eur Med Chem 2016;110:151–163.
207. Page MGP, Dantier C, Desarbre E. in vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 2010;54:2291–2302.
208. Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 2010;65:266–270.
209. Higgins PG, Stefanik D, Page MGP, Hackel M, Seifert H. in vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 2012;67:1167–1169.
210. Mima T, Kvitko BH, Rholl DA, Page MGP, Desabre E, Schweizer HP. in vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 2011;38:157–159.
211. Mushtaq S, Woodford N, Hope R, Adkin R, Livermore DM. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother 2013;68:1601–1608.
212. Hofer B, Dantier C, Gebhardt K, Desarbre E, Hoffmann-Schmitt A, Page MGP. Combined effects of the siderophore monosulfactam BAL30072 and carbapanems on multidrug-resistant Gram-negative bacilli. J Antimicrob Chemother 2013;68:1120–1129.
213. Hornsey M, Phee L, Stubbings W, Wareham DW. in vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. Int J Antimicrob Agents 2013;42:343–346.
214. Russo TA, Page MGP, Beanan JM, Olson R, Hujer AM, Hujer KM, Jacobs M, Bajaksouzian S, Endimiani A, Bonomo R. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother 2011;66:867–873.
215. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci USA 2013;110:16808–16813.
216. Gonzales PR, Pesesky MW, Bouley R, Ballard A, Biddy BA, Suckow MA, Wolter WR, Schroeder VA, Burnham CA, Mobashery S, Chang M, Dantas G. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol 2015;11:855–861.
217. Fishovitz J, Taghizadeh N, Fisher JF, Chang M, Mobashery S. The tipper-strominger hypothesis and triggering of allostery in penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus (MRSA). J Am Chem Soc 2015;137:6500–6505.
218. Bouley R, Kumarasiri M, Peng Z, Otero LH, Song W, Suckow MA, Schroeder VA, Wolter WR, Lastochkin E, Antunes NT, Pi H, Vakulenko S, Hermoso JA, Chang M, Mobashery S. Discovery of antibiotic (E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one. J Am Chem Soc 2015;137:1738–1741.
219. Bush K. Overcoming β-lactam resistance in Gram-negative pathogens. Future Med Chem 2016;8:921–924.